Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Medical Device

Medtronic’s BrainSense Technologies Win EU, UK CE Mark for Parkinson’s Treatment

Fineline Cube Jan 14, 2025

US-Irish firm Medtronic (NYSE: MDT) has announced that it has received CE (Conformité Européenne) Mark...

Company Deals

Sansure Biotech to Acquire Sinobioway Hygene for $110M to Boost Product Pipeline

Fineline Cube Jan 14, 2025

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced plans to acquire 100%...

Company Drug

Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA

Fineline Cube Jan 14, 2025

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative...

Company Drug

Merck’s Keytruda Gains NMPA Approval for HNSCC Indication in China

Fineline Cube Jan 14, 2025

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced that it has received...

Company Drug

Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors

Fineline Cube Jan 14, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals Drug

Zhaoke Ophthalmology Partners with AFT for Brimochol PF Distribution in ANZ

Fineline Cube Jan 14, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a strategic distribution and supply agreement with...

Company Drug

Tonghua Dongbao Begins Phase II Trial for GLP-1/GIP Agonist THDBH120 in Weight Loss

Fineline Cube Jan 14, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced a significant milestone in its clinical development...

Company Deals

Neo Modulus Secures $40.9M Series C Funding for Regenerative Medical Devices

Fineline Cube Jan 14, 2025

Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd., a prominent developer of regenerative implantable medical devices...

Company Deals

MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors

Fineline Cube Jan 14, 2025

Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...

Company Deals

Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500

Fineline Cube Jan 14, 2025

China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...

Company Drug

CSPC’s Prusogliptin Approved in China for Type 2 Diabetes Treatment

Fineline Cube Jan 14, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co.,...

Company Deals

3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303

Fineline Cube Jan 14, 2025

China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...

Company Deals Medical Device

CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion

Fineline Cube Jan 14, 2025

CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in...

Company Drug

JW Therapeutics’ Carteyva Granted Breakthrough Therapy Designation by CDE

Fineline Cube Jan 13, 2025

China-based JW Therapeutics (HKG: 2126) has announced that its Carteyva (relmacabtagene autoleucel injection) has been...

Company Drug

CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval

Fineline Cube Jan 13, 2025

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...

Company Deals

Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership

Fineline Cube Jan 13, 2025

China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...

Company Medical Device

Johnson & Johnson MedTech’s Dual Energy Catheter Gains CE Mark

Fineline Cube Jan 13, 2025

US major Johnson & Johnson MedTech has announced that its Dual Energy THERMOCOOL SMARTTOUCH SF...

Company Drug

Henlius Biotech Gains NMPA Clearance for HLX43 ADC Study

Fineline Cube Jan 13, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clearance from...

Company Deals

Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development

Fineline Cube Jan 13, 2025

China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal...

Company Deals Drug

Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases

Fineline Cube Jan 13, 2025

US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology...

Posts pagination

1 … 218 219 220 … 656

Recent updates

  • NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
  • Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
  • AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.